Suchergebnisse

Concise introductions to the main issues in energy policy and their interaction with environmental policies in the EU. The European Union (EU) faces critical challenges in energy policy making, the most pressing of which are how to achieve the deep greenhouse gas reductions promised at the December 2015 UN Conference of the Parties in Paris, and how this effort can be coordinated with already existing policies. Energy policy is primarily a member state responsibility, and policy makers need an overarching view of the main issues in energy policy and their interaction with environmental policies. This volume aims to fill this need, offering concise introductions to some of the major issues as well as practical suggestions for policy making. The contributors discuss reforms to the EU Emissions Trading System (ETS), the world's largest carbon market; ways to improve the operation and integration of the EU's power grids, in terms of both supply and demand; changes to the EU's Energy Tax Directive, which sets tax floors for fuels outside the ETS; the coordination of climate policies with policies to promote renewables and energy efficiency; research into clean technology; challenges to shale gas development; and transportation policy and the need for action on such externalities as traffic congestion. Finally, contributors consider obstacles to reform, including its potential effects on vulnerable households and energy-intensive industries.

AbstractThe modern presidency is one of administration, where presidents seek to further their own agendas by directing administrative behavior throughout the executive branch. Yet little research explores how executive agencies organize their policy processes in response to publicly articulated presidential priorities. Using two novel datasets that allow us to examine the regulatory priorities of presidents and how executive agencies organize their rulemaking processes, we find that executive agencies respond to presidential policy preferences by centralizing policymaking to the top of an agency's hierarchy, placing regulation in the hands of political appointees.

Research in regulation / George C. Eads -- Information, uncertainty, and regulation / Randall K. Bartlett with assistance from Uday M. Apte -- Transition costs of changing regulations / Robert Dorfman -- Congress, regulation, and the courts / Barry R. Weingast and Kent S. Hall -- The behavior of regulatory agencies / Wesley A. Magat and Steven Estomin -- Experimental methods in political economy / Charles R. Plott -- Setting regulatory priorities / Anthony C. Fisher, Alan Krupnick, and Allen R. Ferguson -- Priorities for research on the benefits of health, safety, and environmental regulation / James W. Vaupel -- Regulation and distribution / David Harrison, Jr

This paper presents a regulatory priority model and its operationalization for pipeline safety. It begins with a brief discussion of pipeline systems and regulatory legislation associated with pipeline safety. The systems transport natural gas, liquid crude oil, gasoline and other liquid hazardous petroleum products. The regulations relate to technologies to be used, human factors, research requirements and environmental protection considerations. The legislative focus is on public safety, property damage and, most recently, environmental protection. Using a risk assessment approach to operationalize the model requires integration of concepts from engineering, economics and ecology. The specific measures applied include reliability, vulnerability and resiliency. Congressional, private industry and Department of Transportation (DOT) regulatory priorities are compared. The paper concludes with the risk assessment implementation strategy by the DOT Office of Pipeline Safety.

This paper compares the quality and use of regulatory analysis accompanying economically significant regulations proposed by US executive branch agencies in 2008, 2009, and 2010. We find that the quality of regulatory analysis is generally low, but varies widely. Budget regulations, which define how the federal government will spend money or collect revenues, have much lower-quality analysis than other regulations. The Bush administration's "midnight" regulations finalized between Election Day and Inauguration Day, along with other regulations left for the Obama administration to finalize, tended to have lower-quality analysis. Most differences between the Bush and Obama administrations depend on agencies' policy preferences. More conservative agencies tended to produce better analysis in the Obama administration, and more liberal agencies tended to do so in the Bush administration. This suggests that agencies more central to an administration's policy priorities do not have to produce as good an analysis to get their regulations promulgated. Adapted from the source document.

Access to quality-assured medical products improves health and save lives. However, one third of the world's population lacks timely access to quality-assured medicines while estimates indicate that at least 10% of medicine in low- and middle-income countries (LMICs) are substandard or falsified (SF), costing approximately US$ 31 billion annually. National regulatory authorities are the key government institutions that promote access to quality-assured medicines and combat SF medical products but despite progress, regulatory capacity in LMICs is still insufficient. Continued and increased investment in regulatory system strengthening (RSS) is needed. We have therefore reviewed existing global normative documents and resources and engaged with our networks of global partners and stakeholders to identify three critical challenges being faced by NRAs in LMICs that are limiting access to medical products and impeding detection of and response to SF medicines. The challenges are; implementing value-added regulatory practices that best utilize available resources, a lack of timely access to new, quality medical products, and limited evidence-based data to support post-marketing regulatory actions. To address these challenges, we have identified seven focused strategies; advancing and leveraging convergence and reliance initiatives, institutionalizing sustainability, utilizing risk-based approaches for resource allocation, strengthening registration efficiency and timeliness, strengthening inspection capacity and effectiveness, developing and implementing risk-based post-marketing quality surveillance systems, and strengthening regulatory management of manufacturing variations. These proposed solutions are underpinned by 13 focused recommendations, which we believe, if financed, technically supported and implemented, will lead to stronger health system and as a consequence, positive health outcomes.

Access to quality-assured medical products improves health and save lives. However, one third of the world's population lacks timely access to quality-assured medicines while estimates indicate that at least 10% of medicine in low- and middle-income countries (LMICs) are substandard or falsified (SF), costing approximately US$ 31 billion annually. National regulatory authorities are the key government institutions that promote access to quality-assured medicines and combat SF medical products but despite progress, regulatory capacity in LMICs is still insufficient. Continued and increased investment in regulatory system strengthening (RSS) is needed. We have therefore reviewed existing global normative documents and resources and engaged with our networks of global partners and stakeholders to identify three critical challenges being faced by NRAs in LMICs that are limiting access to medical products and impeding detection of and response to SF medicines. The challenges are; implementing value-added regulatory practices that best utilize available resources, a lack of timely access to new, quality medical products, and limited evidence-based data to support post-marketing regulatory actions. To address these challenges, we have identified seven focused strategies; advancing and leveraging convergence and reliance initiatives, institutionalizing sustainability, utilizing risk-based approaches for resource allocation, strengthening registration efficiency and timeliness, strengthening inspection capacity and effectiveness, developing and implementing risk-based post-marketing quality surveillance systems, and strengthening regulatory management of manufacturing variations. These proposed solutions are underpinned by 13 focused recommendations, which we believe, if financed, technically supported and implemented, will lead to stronger health system and as a consequence, positive health outcomes.